Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305630 · ClinicalTrials.gov registry record · Phase 2
Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00305630: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00305630 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305630, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD). Patients undergoing PDT are randomized to either a periocular corticosteroid injection with 40 mg of triamcinolone acetonide or observation just prior to PDT. Patients are followed for 6 months. Primary outcome is leakage from choroidal neovascularization (CNV) at 3 months on fluorescein angiography.
Interventions
- DRUG Periocular injection of triamcinolone acetonide 40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305630
The ClinicalTrials.gov registry entry for NCT00305630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Periocular injection of triamcinolone acetonide 40mg is the first listed.
NCT00305630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305630 about?
NCT00305630 is a clinical study titled "Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)". Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD). Patients undergoing PDT are randomized to either a periocular corticosteroid injection with 40 mg of triamcinol...
What is the current status of trial NCT00305630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2002-07. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00305630?
The interventions under investigation include: Periocular injection of triamcinolone acetonide 40mg (DRUG).
Who is sponsoring clinical trial NCT00305630?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.